Skip to main content

Peptide Profile

Gonadorelin

GnRH · Luteinizing Hormone-Releasing Hormone · LHRH

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a…

Reproductive & HormonalNot EvaluatedCompoundable
Used forsexual health
Half-life
~2-4 minutes
Routes
subcutaneous, intravenous
Find providers View evidence

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What Gonadorelin is

About Gonadorelin

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin in TRT support contexts: gonadorelin is used off-label in men on testosterone replacement therapy to maintain testicular function and endogenous LH/FSH signaling. No FDA-approved protocol exists for this indication; dosing and administration schedule are provider-determined. This application requires physician supervision due to the mechanistic sensitivity to delivery pattern: continuous administration produces paradoxical gonadotropin suppression, making timing and pulse frequency clinically critical considerations. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Women's Health

Pulsatile gonadorelin (native GnRH decapeptide) is evidenced for ovulation induction specifically in hypothalamic amenorrhea (small cohort study, 7 of 12 women achieving pregnancy). Prescribing guidance is to discontinue once pregnancy is achieved; no data support administration during pregnancy.

Gonadorelin Benefits & Research Areas

pulsatile LH and FSH stimulation from the pituitarytesticular function and testosterone production maintenancefertility preservation alongside TRT (FSH pathway intact)hypothalamic-pituitary axis restoration in hypogonadism

Research Signals

Commonly researched in the context of

Hormonal Changes

Population research notes

18–2930s40s50+

These signals reflect research interest areas, not treatment indications.

Pharmacokinetics

Gonadorelin half-life calculator

Compound & timing

Half-lifefrom PeptideBase data
Source: "~2-4 minutes" · Gonadorelin (PeptideBase)
to show amount remaining
4 min
0%25%50%75%100%04.28.3121721time since dose (min)
Plasma decay curve for Gonadorelin: 25% to 50% remaining at 4 min after the dose.
range (~2-4 minutes)slower half-life
25%–50%remaining in plasmaat 4 min after the dose
Half-life
2 – 4 min
~97% cleared after
20 min

Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.

The Research

What the evidence says about Gonadorelin

Research Evidence

based on 3 studies · most recent 2026

Regulatory Status

Availability Status
Compoundable
FDA Status
Not Evaluated

Previously FDA-approved as Factrel (NDA 017019). Voluntarily discontinued by manufacturer. Included on the FDA 503B outsourcing-facility bulk-substances list (Category 1), not the 503A pharmacy list. Prescription compounded product.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

3 sources cited · 1 strong · 2 weak

1 Meta-analysis · 2 Animals

  • Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis

    Fertility and Sterility · 2018

    This systematic review and meta-analysis of 35 studies encompassing 1,002 women with hypothalamic amenorrhea found that pulsatile gonadorelin (GnRH) treatment achieved high ovulation rates with a trend toward high pregnancy and live birth rates, low OHSS incidence, and low multiple gestation rates, establishing it as an effective and safe first-line ovulation induction strategy.

    Meta-analysisn=1,002StrongPMID 29605411

  • Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: comparison of dosage and frequency.

    J Reprod Dev · 2026

    # Summary Research found that administering a GnRH analogue (dephereline) during the early luteal phase after insemination improved pregnancy outcomes in repeat-breeder cows by significantly increasing corpus luteum formation and reducing pregnancy loss compared to control animals. This study demonstrated that both elevated-dose treatment protocols were similarly effective at enhancing pregnancy maintenance in this subfertile population.

    AnimalWeakPMID 42091524

  • Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows.

    J Dairy Sci · 2026

    AnimalWeakPMID 41698585

Gonadorelin Side Effects & Safety Considerations

Research-use compound with limited human data. Evidence strength varies — see the Evidence section.

Reported (unverified — pending clinical review)

continuous high-dose (causes receptor downregulation)

No established clinical contraindications

Common monitoring markers in research protocols

Standard reproductive endocrinology panels establish HPG axis baseline. LH and FSH confirm pituitary response to gonadorelin; testosterone, E2, and SHBG reflect downstream gonadal output.

Total testosteroneLHFSHEstradiol (E2)SHBGProlactin

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Compare

VS

Gonadorelin

Certificates of Analysis

1 COA on record for Gonadorelin

PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Frequently Asked Questions — Gonadorelin

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism.

pulsatile LH and FSH stimulation from the pituitary, testicular function and testosterone production maintenance, fertility preservation alongside TRT (FSH pathway intact), hypothalamic-pituitary axis restoration in hypogonadism.

Research on Gonadorelin primarily documents effects related to pulsatile LH and FSH stimulation from the pituitary and testicular function and testosterone production maintenance and fertility preservation alongside TRT (FSH pathway intact) and hypothalamic-pituitary axis restoration in hypogonadism. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Gonadorelin include continuous high-dose (causes receptor downregulation). This is educational information only — consult a qualified healthcare professional before use.

For Gonadorelin, its FDA status is not evaluated by the FDA, and it is available through compounding pharmacies. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

18 providers in the directory currently offer Gonadorelin.

Across 10 research vendors tracked on PeptideBase, Gonadorelin has a median price of about $8.45 per mg, typically ranging $6.90–$14.95 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

This systematic review and meta-analysis of 35 studies encompassing 1,002 women with hypothalamic amenorrhea found that pulsatile gonadorelin (GnRH) treatment achieved high ovulation rates with a trend toward high pregnancy and live birth rates, low OHSS incidence, and low multiple gestation rates, establishing it as an effective and safe first-line ovulation induction strategy.

Gonadorelin is featured in the following research stacks on PeptideBase: Melanotan II + Gonadorelin: Central & Hormonal Sexual Health.

Access

How to get Gonadorelin

Market Pricing

10 vendors
$6.90/mgBudget
$8.45/mgMedian
$14.95/mgPremium
$6.90
$8.45
$14.95

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified August 2026 · Gonadorelin price intelligence

Compare 10 vendors →
Compare all 10 vendors →

Where to buy Gonadorelin

18 providers
●14 Clinics●2 Pharmacies●2 Online Vendors26 in stock
View all 18 providers →

Research stacks

Browse all →

Commonly stacked with

Melanotan II

Questions to ask your provider

Stay updated on Gonadorelin providers

New providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Keep exploring

Tools & Guides

Reconstitution Calculator

Convert vial size + BAC water volume into draw volume.

How to Reconstitute Peptides

Step-by-step guide: BAC water, vial prep, and storage after mixing.

Peptide Dosage Guide

Key factors that determine dosing in clinical practice.

Peptide Storage Guide

How to store lyophilized and reconstituted peptides.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Gonadorelin — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/gonadorelin
https://peptidebase.io/peptides/gonadorelinMethodologyLicenseDownload JSONDownload CSV

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.